Human CD229/SLAMF3 Alexa Fluor® 350-conjugated Antibody Summary
Accession # Q9HBG7
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Preparation and Storage
CD229, also known as Ly9 and SLAMF3, is a 120 kDa type I transmembrane glycoprotein in the SLAM subgroup of the CD2 family (1). Mature human CD229 consists of a 407 amino acid (aa) extracellular domain (ECD) with two Ig‑like V-set and two Ig‑like truncated C2-set domains. It also shows a 22 aa transmembrane segment, and a 179 aa cytoplasmic domain with two immunoreceptor tyrosine-based switch motifs ITSMs (2, 3). The ECD of human CD229 shares 57%‑59% aa sequence identity with mouse and rat CD229. Within the first two Ig‑like domains that are common to all SLAM proteins, human CD229 shares 24%‑39% aa sequence identity with human 2B4, BLAME, CD2F-10, CD84, CRACC, NTB-A, and SLAM. Alternate splicing generates two additional isoforms that lack the juxtamembrane Ig‑like domain or short cytoplasmic region (2). CD229 is expressed on T and B cells, thymocytes, and more weakly on NK cells (2‑6). Homophilic binding between CD229 molecules is mediated by the N-terminal Ig‑like domain (7). Human and mouse CD229 exhibit cross-species binding (7). Antigen stimulation of lymphocytes induces CD229 clustering to sites of T cell‑B cell contact (7). Two tyrosines in the cytoplasmic domain are required for association of CD229 with the adaptor proteins AP-2 (μ2 chain) and GRB-2 and both are required for CD229 internalization (8, 9). In addition, there are two ITSMs which mediate phosphorylation-dependent CD229 association with SAP and SHP-2 (10). These four tyrosine-containing motifs are intact in the described CD229 splice variants. CD229 knockout mice show minimally impaired immune responses, suggesting functional redundancy with other molecules (11).
- Bhat, R. et al. (2006) J. Leukoc. Biol. 79:417.
- de la Fuente, M.A. et al. (2001) Blood 97:3513.
- Sandrin, M.S. et al. (1992) J. Immunol. 149:1636.
- Romero, X. et al. (2004) Tissue Antigens 64:132.
- Hogarth, P.M. et al. (1980) Immunogenetics 11:65.
- Mathieson, B.J. et al. (1980) J. Immunol. 125:2127.
- Romero, X. et al. (2005) J. Immunol. 174:7033.
- Del Valle, J.M. et al. (2003) J. Biol. Chem. 278:17430.
- Martin, M. et al. (2005) J. Immunol. 174:5977.
- Sayos, J. et al. (2001) Blood 97:3867.
- Graham, D.B. et al. (2006) J. Immunol. 176:291.
No product specific FAQs exist for this product, however you mayView all Antibody FAQs
Reviews for Human CD229/SLAMF3 Alexa Fluor® 350-conjugated Antibody
There are currently no reviews for this product. Be the first to review Human CD229/SLAMF3 Alexa Fluor® 350-conjugated Antibody and earn rewards!
Have you used Human CD229/SLAMF3 Alexa Fluor® 350-conjugated Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image